After intraperitoneal or intravenous administration of MV-NIS in ovarian cancer or multiple myeloma patients, respectively, positive SPECT/CT scans indicated viral gene expression at the tumor site in a subset of patients [25, 26]. This evidence concerns the gene SLC5A5 and AL amyloidosis.